Clinical Trials Browser

Phase 1/2 × INDUSTRY × TQ-B3525 × Clear all

NCT04355520 2020-04-21

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Phase 1/2 Unknown

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer